Skip to main content

Melanoma

Clinical Trials, Melanoma

Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy

Meeting Highlights

NCCN Highlights, Melanoma

New Standards of Care for Melanoma

FDA Oncology Update, Melanoma, Immunotherapy

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Case Reports, Adverse Events, Melanoma, Checkpoint Inhibitors

Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine

Parikshit Padhi, MD, MBBS, Traci M. White, PharmD, PhC, BCGP, Neslihan Cetin, MD

Parikshit Padhi, MD, MBBS; Traci M. White, PharmD, PhC, BCGP; Neslihan Cetin, MD

Melanoma

Real-World Analysis Finds That Dabrafenib/Trametinib Combination Is Effective in Patients with BRAF V600-Mutated Melanoma with Brain Metastases

Melanoma

Effectiveness of Dual Immunotherapy Confirmed for Patients with Metastatic Melanoma and Autoimmune Disease

Melanoma

Symptoms from Immunotherapy/Targeted Therapy Most Mentioned Topic by Patients with Melanoma on Health-Related Social Media

Melanoma

Complete Responses Equally Durable with Shorter versus Longer Immunotherapy Courses in Advanced Melanoma

Melanoma

Combination Ipilimumab/Nivolumab Better Than Single-Agent Anti–PD-1 Regardless of BRAF Status in Advanced Melanoma

Melanoma

Meaningful Response Possible with Third-Line Targeted Therapy Rechallenge for Patients with BRAF-Mutation–Positive Advanced Melanoma

1
2

Page 1 of 2
Results 1 - 10 of 17